1-chloro-2,4-diisopropylbenzene | 82146-18-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-chloro-2,4-diisopropylbenzene
• 英文别名: 4-Chlor-1,3-diisopropyl-benzol；Diisopropyl-chlor-benzol；isopropyl-p-isopropyl chlorobenzene；1-chloro-2,4-di(propan-2-yl)benzene
• CAS: 82146-18-7
• 化学式: C₁₂H₁₇Cl
• 分子量: 196.72
• InChiKey: COVLIGFZJREENS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-chloro-2,4-diisopropylbenzene 生成 1-chloro-2,5-diisopropylbenzene
  参考文献：
  名称：

  来自平衡测量的异丙基氯苯的形成摩尔焓

  摘要：

  摘要 研究了 1-氯-3-异丙基-4-甲基苯 (I) 和 1-氯-2-异丙基-4-甲基苯、1-氯-2,6-二异丙基-4-甲基苯 (III) 之间的异构化平衡。 )和1-氯-2,5-二异丙基-4-甲基苯(IV)，以及1-氯-3,5-二异丙基-4-甲基苯(V)和(IV)之间。还研究了 (IV) 与 1-氯-4-甲基苯 (VI) 与 (I) 和 (II) 形成的相互作用。这些实验是针对 303 到 403 K 之间的液态化合物进行的。根据平衡常数的值，已经计算出以下对 Δ r H mo /(kJ·mol -1 ) 和 Δ r S 的结果mo /(J·K -1 ·mol -1 ): I = II, -(3.12 ± 1.08) 和 (4.04 ± 3.18); III = IV, (0.43 ± 0.17) 和 (2.68 ± 0.25)；V = IV，-(10.08 ± 4.86) 和 (5.40

  DOI：

  10.1016/0021-9614(85)90118-1

文献信息

• NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：AHN-GOOK PHARMACEUTICAL CO., LTD.

  公开号：US20150210635A1

  公开（公告）日：2015-07-30

  The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

  本发明涉及一种新颖的化合物或其药物可接受的盐，该化合物抑制11β-HSD1酶活性，其制备方法，以及包含该化合物作为活性成分的药物组合物。由于本发明的化合物选择性地抑制11β-HSD1（11β-羟基类固醇脱氢酶1型）的活性，因此本发明的化合物可以有效地用作治疗由11β-HSD1过度激活引起的疾病的治疗剂，例如非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由糖皮质激素过度活动介导的疾病或状况。
• PHENYL C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF
  申请人：Zhao Guilong

  公开号：US20130023486A1

  公开（公告）日：2013-01-24

  The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of R 5 and R 6 are selected from the following: (1) R5=R6=Me; (2) R5=Me, R6=OMe; (3) R5=Me, R6=H; (4) R5=Me, R6=F; (5) R5=F, R6=H; and (6) R5=OMe, R6=H.

  该发明涉及一种具有苯基C-葡萄苷结构的钠葡萄糖共转运蛋白2（SGLT2）抑制剂，其制备方法，含有该抑制剂的药物组合物，以及其在治疗糖尿病和制备抗糖尿病药物中的用途。该发明提供了一种具有一般式I结构的化合物及其药用盐和前药酯，其中，R5和R6的定义从以下选定：（1）R5=R6=Me；（2）R5=Me，R6=OMe；（3）R5=Me，R6=H；（4）R5=Me，R6=F；（5）R5=F，R6=H；和（6）R5=OMe，R6=H。
• N-Phenyloxamide derivatives
  申请人：YAMAGUCHI Youichi

  公开号：US20080249175A1

  公开（公告）日：2008-10-09

  A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R 1 represents a C 6-10 aryl group; or a C 6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, cyano group, nitro group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group and a C 1-6 alkylsulfanyl group, R 2 represents a C 6-10 aryl group; or a C 6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, hydroxy group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group, a C 1-6 alkylsulfanyl group and phenyl group, X represents a single bond or oxygen atom, Z represents a phenylene group or a substituted phenylene group, m represents 0 or 1.

  由以下一般式(I)表示的化合物或其盐，或其水合物或其溶剂合物，具有对纤溶酶原激活酶抑制剂-1（PAI-1）的抑制作用：其中R1表示一个C6-10芳基团；或一个C6-10芳基团，该芳基团取代为从卤原子、氰基、硝基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基和C1-6烷基硫基等组成的组或组合物，R2表示一个C6-10芳基团；或一个C6-10芳基团，该芳基团取代为从卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基硫基和苯基等组成的组或组合物，X表示一个单键或氧原子，Z表示一个苯基或取代苯基，m表示0或1。
• INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160122323A1

  公开（公告）日：2016-05-05

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式（I）的新型化合物及其药学上可接受的盐、溶剂合物、水合物、多晶形、共晶体、互变异构体、立体异构体、同位素标记衍生物、前药和其组合物。本发明还提供了使用所述创新化合物或组合物治疗或预防增殖性疾病（例如，癌症（例如，白血病、淋巴瘤、黑色素瘤、多发性骨髓瘤、乳腺癌、尤因氏肉瘤、骨肉瘤、脑癌、神经母细胞瘤、肺癌）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可以抑制激酶的异常活性，例如细胞周期依赖性激酶（CDK）（例如细胞周期依赖性激酶7（CDK7）），从而在受试者中诱导细胞凋亡和/或抑制转录。
• Method for producing an aromatic compound having an alkyl group with at least three carbon atoms
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0985649A2

  公开（公告）日：2000-03-15

  Aromatic compounds having an alkyl group with at least 3 carbon atoms are produced in a process comprising at least one of the following steps: (1) a step of contacting a starting material that contains an aromatic compound having a branched alkyl group with at least 3 carbon atoms, with a zeolite-containing catalyst in a liquid phase in the presence of hydrogen therein, thereby changing the position of the carbon atoms of the alkyl group bonding to the aromatic ring of the compound; (2) a step of contacting a starting material that contains an aromatic compound having a branched alkyl group with at least 3 carbon atoms, with a catalyst containing zeolite and containing rhenium and/or silver, in a liquid phase, thereby changing the position of the carbon atoms of the alkyl group bonding to the aromatic ring of the compound; (3) a step of contacting a halogenated aromatic compound having an alkyl group with at least 3 carbon atoms, with an acid-type catalyst, thereby isomerizing the compound; and (4) a step of treating a mixture of isomers of an aromatic compound having an alkyl group with at least 3 carbon atoms, with a zeolite adsorbent that contains at least one exchangable cation selected from alkali metals, alkaline earth metals, lead, thallium and silver, thereby separating a specific isomer from the isomer mixture through adsorption.

  具有至少 3 个碳原子烷基的芳香族化合物的生产工艺至少包括以下一个步骤： (1) 将含有至少 3 个碳原子的支链烷基的芳香族化合物的起始原料在液相中与含沸石的催化剂在氢存在的情况下接触，从而改变烷基的碳原子与化合物的芳香环键合的位置； (2) 将含有芳香族化合物的起始原料与含沸石和含铼和/或银的催化剂在液相中接触，该芳香族化合物具有至少 3 个碳原子的支链烷基，从而改变烷基碳原子与化合物芳香环键合的位置； (3) 将具有至少 3 个碳原子的烷基的卤代芳香族化合物与酸型催化剂接触，从而使该化合物异构化；以及 (4) 用沸石吸附剂处理具有至少 3 个碳原子的烷基的芳香族化合物的异构体混合物，该沸石吸附剂含有至少一种选自碱金属、碱土金属、铅、铊和银的可交换阳离子，从而通过吸附从异构体混合物中分离出特定的异构体。